REFERENCES
1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231-51.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20.
3. Feldheim J, Kessler AF, Monoranu CM, Ernestus RI, Löhr M, Hagemann C. Changes of O6-Methylguanine DNA Methyltransferase (MGMT) promoter methylation in glioblastoma relapse-a meta-analysis type literature review. Cancers (Basel) 2019;11:1837.
4. Indraccolo S, Lombardi G, Fassan M, et al. Genetic, epigenetic, and immunologic profiling of MMR-deficient relapsed glioblastoma. Clin Cancer Res 2019;25:1828-37.
5. Du Z, Brown BP, Kim S, et al. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nat Commun 2021;12:1382.
6. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
7. Jiang T, Wang G, Liu Y, et al. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharmaceutica Sinica B 2021;11:355-72.
8. Curry RN, Glasgow SM. The role of neurodevelopmental pathways in brain tumors. Front Cell Dev Biol 2021;9:659055.
9. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
11. Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov 2021;20:125-44.
12. Liu Z, Brunskill E, Varnum-Finney B, et al. The intracellular domains of Notch1 and Notch2 are functionally equivalent during development and carcinogenesis. Development 2015;142:2452-63.
13. Aster JC, Pear WS, Blacklow SC. The varied roles of Notch in cancer. Annu Rev Pathol 2017;12:245-75.
14. Lovschall H, Mitsiadis TA, Poulsen K, Jensen KH, Kjeldsen AL. Coexpression of Notch3 and Rgs5 in the pericyte-vascular smooth muscle cell axis in response to pulp injury. Int J Dev Biol 2007;51:715-21.
17. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000;26:484-9.
18. Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci 2021;277:119504.
19. Krishna BM, Jana S, Singhal J, et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Lett 2019;461:123-31.
20. Montalto FI, Giordano F, Chiodo C, et al. Progesterone receptor b signaling reduces breast cancer cell aggressiveness: role of cyclin-D1/Cdk4 mediating paxillin phosphorylation. Cancers (Basel) 2019;11:1201.
21. Casimiro MC, Di Sante G, Crosariol M, et al. Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis. Oncotarget 2015;6:8525-38.
22. Saiki W, Ma C, Okajima T, Takeuchi H. Current views on the roles of O-Glycosylation in controlling notch-ligand interactions. Biomolecules 2021;11:309.
23. Bertrand FE. The cross-talk of NOTCH and GSK-3 signaling in colon and other cancers. Biochim Biophys Acta Mol Cell Res 2020;1867:118738.
24. Tabatabai G, Wakimoto H. Glioblastoma: state of the art and future perspectives. Cancers (Basel) 2019;11:1091.
25. Wang L, Wu Q, Zhu S et al. Delta/notch-like epidermal growth factor-related receptor (DNER) orchestrates stemness and cancer progression in prostate cancer. Am J Transl Res 2017;9:5031-9.
26. Sharma A, Mir R, Galande S. Epigenetic regulation of the Wnt/β-catenin signaling pathway in cancer. Front Genet 2021;12:681053.
27. Luo K. Signaling cross talk between TGF-β/Smad and other signaling pathways. Cold Spring Harb Perspect Biol 2017;9:a022137.
28. Francesco EM, Maggiolini M, Musti AM. Crosstalk between Notch, HIF-1α and GPER in breast cancer EMT. Int J Mol Sci 2018;19:2011.
29. Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G. The Notch pathway in colorectal cancer. Int J Cancer 2016;138:1835-42.
30. Mollen EWJ, Ient J, Tjan-Heijnen VCG, et al. Moving breast cancer therapy up a Notch. Front Oncol 2018;8:518.
31. Kwon OJ, Zhang L, Wang J, et al. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest 2016;126:2626-41.
32. Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? Front Oncol 2018;8:267.
33. Bazzoni R, Bentivegna A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel) 2019;11:292.
34. Gersey Z, Osiason AD, Bloom L, et al. Therapeutic targeting of the Notch pathway in glioblastoma multiforme. World Neurosurg 2019;131:252-263.e2.
35. Kulic I, Robertson G, Chang L, et al. Loss of the notch effector RBPJ promotes tumorigenesis. J Exp Med 2015;212:37-52.
37. Fukusumi T, Califano JA. The NOTCH pathway in head and neck squamous cell carcinoma. J Dent Res 2018;97:645-53.
38. Xiu MX, Liu YM, Kuang BH. The oncogenic role of Jagged1/Notch signaling in cancer. Biomed Pharmacother 2020;129:110416.
39. Zhu H, Zhou X, Redfield S et al. Elevated jagged-1 and notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res 2013;5:368-78.
40. Shi TP, Xu H, Wei JF, et al. Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol 2008;180:361-6.
41. Aburjania Z, Jang S, Whitt J, Jaskula-Stzul R, Chen H, Rose JB. The role of notch3 in cancer. Oncologist 2018;23:900-11.
42. Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol 2010;117:409-16.
43. Lu QR, Qian L, Zhou X. Developmental origins and oncogenic pathways in malignant brain tumors. Wiley Interdiscip Rev Dev Biol 2019;8:e342.
44. Oldrini B, Schuhmacher AJ, Squatrito M. Take it down a NOTCH in forebrain tumors. Cancer Cell 2015;28:681-2.
45. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
46. De Amicis F, Guido C, Santoro M, et al. A novel functional interplay between Progesterone Receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cells. J Cell Mol Med 2014;18:2252-65.
47. Parmigiani E, Taylor V, Giachino C. Oncogenic and tumor-suppressive functions of NOTCH signaling in glioma. Cells 2020;9:2304.
48. Xing ZY, Sun LG, Guo WJ. Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multiforme patients. Clin Neurol Neurosurg 2015;131:54-8.
49. Noor H, Whittaker S, McDonald KL. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis. Genomics 2022;114:110289.
50. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52.
51. Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev 2019;33:591-609.
52. Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma. Cells 2021;10:621.
53. Passaro AP, Lebos AL, Yao Y, Stice SL. Immune response in neurological pathology: emerging role of central and peripheral immune crosstalk. Front Immunol 2021;12:676621.
54. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 2017;28:1457-72.
55. Garner JM, Ellison DW, Finkelstein D, et al. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations. PLoS ONE 2015;10:e0125838.
56. Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol 2022;24:669-82.
57. Zhang C, Martinez-Ledesma E, Gao F et al. Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Am J Cancer Res 2019;9:1734-45.
58. Jiang X, Xing H, Kim TM, et al. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells 2012;30:1313-26.
59. Qiang L, Wu T, Zhang HW, et al. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 2012;19:284-94.
60. Ojha R, Tantray I, Rimal S, Mitra S, Cheshier S, Lu B. Regulation of reverse electron transfer at mitochondrial complex I by unconventional Notch action in cancer stem cells. Dev Cell 2022;57:260-276.e9.
61. Pinto G, Saenz-de-Santa-Maria I, Chastagner P, et al. Patient-derived glioblastoma stem cells transfer mitochondria through tunneling nanotubes in tumor organoids. Biochem J 2021;478:21-39.
62. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
63. Alafate W, Xu D, Wu W, et al. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. J Exp Clin Cancer Res 2020;39:239.
64. Negri FV, Crafa P, Pedrazzi G, et al. Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. Future Oncol 2015;11:3167-74.
65. Meng RD, Shelton CC, Li YM, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009;69:573-82.
66. Roberts NB, Alqazzaz A, Hwang JR, et al. Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction. J Neurooncol 2018;140:497-507.
67. Cho S, Lu M, He X, et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 2011;108:20778-83.
68. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
69. Wang YC, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010;70:4840-9.
70. Sarkar S, Mirzaei R, Zemp FJ, et al. Activation of NOTCH signaling by tenascin-C promotes growth of human brain tumor-initiating cells. Cancer Res 2017;77:3231-43.
71. Kološa K, Motaln H, Herold-Mende C, Koršič M, Lah TT. Paracrine effects of mesenchymal stem cells induce senescence and differentiation of glioblastoma stem-like cells. Cell Transplant 2015;24:631-44.
72. Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci 2019;20:2746.
73. Guelfi S, Orsetti B, Deleuze V, et al. SLUG and truncated TAL1 reduce glioblastoma stem cell growth downstream of notch1 and define distinct vascular subpopulations in glioblastoma multiforme. Cancers (Basel) 2021;13:5393.
74. Kristoffersen K, Nedergaard MK, Villingshøj M, et al. Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. Cancer Biol Ther 2014;15:862-77.
75. Raghu H, Gondi CS, Dinh DH, Gujrati M, Rao JS. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. Mol Cancer 2011;10:130.
76. Jung E, Osswald M, Ratliff M, et al. Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Nat Commun 2021;12:1014.
77. Audia A, Conroy S, Glass R, Bhat KPL. The impact of the tumor microenvironment on the properties of glioma stem-like cells. Front Oncol 2017;7:143.
78. Peereboom DM, Ye X, Mikkelsen T, et al. A phase ii and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma. Neurosurgery 2021;88:246-51.
79. Xu R, Shimizu F, Hovinga K, et al. Molecular and clinical effects of notch inhibition in glioma patients: a phase 0/I trial. Clin Cancer Res 2016;22:4786-96.
80. Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the Notch transcription factor complex. Proc Natl Acad Sci U S A 2020;117:16292-301.
81. Giordano F, Montalto FI, Panno ML et al. A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis. Am J Cancer Res 2021;11:5933-50.
82. Floyd DH, Kefas B, Seleverstov O, et al. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 2012;14:1215-26.
83. Chang SF, Yang WH, Cheng CY, Luo SJ, Wang TC. γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression. Int J Med Sci 2021;18:2551-60.
84. Nam DH, Jeon HM, Kim S, et al. Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 2008;14:4059-66.
85. Friedman GK, Moore BP, Nan L, et al. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 2016;18:227-35.
86. Teodorczyk M, Schmidt MHH. Notching on cancer’s door: notch signaling in brain tumors. Front Oncol 2014;4:341.
87. Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 2013;6:943-55.
88. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling--are we there yet? Nat Rev Drug Discov 2014;13:357-78.
89. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70:6870-9.
90. Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, et al. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anticancer Drugs 2015;26:272-83.
91. Yahyanejad S, King H, Iglesias VS, et al. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget 2016;7:41251-64.
92. Hovinga KE, Shimizu F, Wang R, et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010;28:1019-29.
93. Staberg M, Michaelsen SR, Olsen LS, et al. Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int 2016;16:34.
94. Monticone M, Biollo E, Fabiano A, et al. z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Mol Cancer Res 2009;7:1822-34.
95. Chu Q, Orr BA, Semenkow S, Bar EE, Eberhart CG. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res 2013;19:3224-33.
96. Strosberg JR, Yeatman T, Weber J, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012;48:997-1003.
97. Pan E, Supko JG, Kaley TJ, et al. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol 2016;130:571-9.
98. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052-7.
99. Aste-Amézaga M, Zhang N, Lineberger JE, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010;5:e9094.
100. Herrera-Rios D, Li G, Khan D, et al. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. Sci Rep 2020;10:16218.
101. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
102. Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53.
103. Conte A, Kisslinger A, Procaccini C, et al. Convergent effects of resveratrol and PYK2 on prostate cells. Int J Mol Sci 2016;17:1542.
104. Amicis F, Chimento A, Montalto FI, Casaburi I, Sirianni R, Pezzi V. Steroid receptor signallings as targets for resveratrol actions in breast and prostate cancer. Int J Mol Sci 2019;20:1087.
105. Ko JH, Sethi G, Um JY, et al. The role of resveratrol in cancer therapy. Int J Mol Sci 2017;18:2589.
106. Lin H, Xiong W, Zhang X, et al. Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncol Rep 2011;26:925-30.
107. Wang J, Yan Z, Liu X, Che S, Wang C, Yao W. Alpinetin targets glioma stem cells by suppressing Notch pathway. Tumour Biol 2016;37:9243-8.
108. Khathayer F, Ray SK. Diosgenin as a novel alternative therapy for inhibition of growth, invasion, and angiogenesis abilities of different glioblastoma cell lines. Neurochem Res 2020;45:2336-51.
109. Kim TJ, Kwon HS, Kang M, Leem HH, Lee KH, Kim DY. The antitumor natural compound falcarindiol disrupts neural stem cell homeostasis by suppressing notch pathway. Int J Mol Sci 2018;19:3432.
110. Wieland A, Trageser D, Gogolok S, et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 2013;19:4124-36.
